401 related articles for article (PubMed ID: 20491785)
1. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
Meraviglia S; Eberl M; Vermijlen D; Todaro M; Buccheri S; Cicero G; La Mendola C; Guggino G; D'Asaro M; Orlando V; Scarpa F; Roberts A; Caccamo N; Stassi G; Dieli F; Hayday AC
Clin Exp Immunol; 2010 Aug; 161(2):290-7. PubMed ID: 20491785
[TBL] [Abstract][Full Text] [Related]
2. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
Dieli F; Vermijlen D; Fulfaro F; Caccamo N; Meraviglia S; Cicero G; Roberts A; Buccheri S; D'Asaro M; Gebbia N; Salerno A; Eberl M; Hayday AC
Cancer Res; 2007 Aug; 67(15):7450-7. PubMed ID: 17671215
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
[TBL] [Abstract][Full Text] [Related]
4. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
Cabillic F; Toutirais O; Lavoué V; de La Pintière CT; Daniel P; Rioux-Leclerc N; Turlin B; Mönkkönen H; Mönkkönen J; Boudjema K; Catros V; Bouet-Toussaint F
Cancer Immunol Immunother; 2010 Nov; 59(11):1611-9. PubMed ID: 20582413
[TBL] [Abstract][Full Text] [Related]
5. Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention?
Gougeon ML; Malkovsky M; Casetti R; Agrati C; Poccia F
Vaccine; 2002 May; 20(15):1938-41. PubMed ID: 11983250
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Mattarollo SR; Kenna T; Nieda M; Nicol AJ
Cancer Immunol Immunother; 2007 Aug; 56(8):1285-97. PubMed ID: 17265022
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G
AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075
[TBL] [Abstract][Full Text] [Related]
8. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
9. Anti-fibrotic characteristics of Vγ9+ γδ T cells in systemic sclerosis.
Markovits N; Bendersky A; Loebstein R; Brusel M; Kessler E; Bank I
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):23-29. PubMed ID: 26886502
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: the role of exogenous IL-2.
Casetti R; Perretta G; Taglioni A; Mattei M; Colizzi V; Dieli F; D'Offizi G; Malkovsky M; Poccia F
J Immunol; 2005 Aug; 175(3):1593-8. PubMed ID: 16034098
[TBL] [Abstract][Full Text] [Related]
11. Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.
Sun L; Li Y; Jiang Z; Zhang J; Li H; Li B; Ye Z
Tumour Biol; 2016 Jun; 37(6):7333-44. PubMed ID: 26676633
[TBL] [Abstract][Full Text] [Related]
12. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
Poonia B; Pauza CD
Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.
Nicol AJ; Tokuyama H; Mattarollo SR; Hagi T; Suzuki K; Yokokawa K; Nieda M
Br J Cancer; 2011 Sep; 105(6):778-86. PubMed ID: 21847128
[TBL] [Abstract][Full Text] [Related]
14. Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.
Dhar S; Chiplunkar SV
Cancer Immun; 2010 Nov; 10():10. PubMed ID: 21069948
[TBL] [Abstract][Full Text] [Related]
15. IL-23R and TCR signaling drives the generation of neonatal Vgamma9Vdelta2 T cells expressing high levels of cytotoxic mediators and producing IFN-gamma and IL-17.
Moens E; Brouwer M; Dimova T; Goldman M; Willems F; Vermijlen D
J Leukoc Biol; 2011 May; 89(5):743-52. PubMed ID: 21330350
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma.
Di Carlo E; Bocca P; Emionite L; Cilli M; Cipollone G; Morandi F; Raffaghello L; Pistoia V; Prigione I
Mol Ther; 2013 May; 21(5):1034-43. PubMed ID: 23481325
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-18 activates Vγ9Vδ2
Murday AS; Chaudhry S; Pauza CD
Immunology; 2017 Aug; 151(4):385-394. PubMed ID: 28342224
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
[TBL] [Abstract][Full Text] [Related]
19. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.
Benzaïd I; Mönkkönen H; Stresing V; Bonnelye E; Green J; Mönkkönen J; Touraine JL; Clézardin P
Cancer Res; 2011 Jul; 71(13):4562-72. PubMed ID: 21646473
[TBL] [Abstract][Full Text] [Related]
20. Expansion of human peripheral blood γδ T cells using zoledronate.
Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
